{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:15:15Z","timestamp":1788401715587,"version":"build-2803163510"},"reference-count":24,"publisher":"American Chemical Society (ACS)","issue":"2","license":[{"start":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T00:00:00Z","timestamp":1513814400000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/pubs.acs.org\/page\/policy\/authorchoice_ccbyncnd_termsofuse.html"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["1R01 AG 030328-01"],"award-info":[{"award-number":["1R01 AG 030328-01"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011272","name":"FP7 Health","doi-asserted-by":"publisher","award":["222980"],"award-info":[{"award-number":["222980"]}],"id":[{"id":"10.13039\/100011272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011272","name":"FP7 Health","doi-asserted-by":"publisher","award":["602812"],"award-info":[{"award-number":["602812"]}],"id":[{"id":"10.13039\/100011272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,2,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glucagon-like peptide-1 receptor (GLP-1R) targeting using radiolabeled exendin is a promising approach to noninvasively visualize and determine beta cell mass (BCM), which could help to unravel the pathophysiology of diabetes. However, saturation of the GLP-1R on beta cells occurs at low peptide doses, since the number of receptors expressed under physiological conditions is low. Therefore, tracers with high specific activities are required to sensitively image small variations in BCM. Here, we describe a novel exendin-3-based radiotracer with multiple chelators and determine its potential for in vivo beta cell imaging. Exendin-3 was modified by adding six lysine residues C-terminally conjugated with one, two, or six DTPA moieties. All compounds were labeled with 111In and their GLP-1R affinity was determined in vitro using GLP-1R expressing cells. The in vivo behavior of the 111In-labeled tracers was examined in BALB\/c nude mice with a subcutaneous GLP-1R expressing tumor (INS-1). Brown Norway rats were used for SPECT visualization of the pancreatic BCM. Addition of six lysine and six DTPA residues (hexendin(40\u201345)) resulted in a 7-fold increase in specific activity (from 0.73 GBq\/nmol to 5.54 GBq\/nmol). IC50 values varied between 5.2 and 69.5 nM. All compounds with two or six lysine and DTPA residues had a significantly lower receptor affinity than [Lys40(DTPA)]exendin-3 (4.4 nM, p &amp;lt; 0.05). The biodistribution in mice revealed no significant decrease in pancreatic uptake after addition of six lysine and DTPA molecules. Hexendin(40\u201345) showed a 6-fold increase in absolute 111In uptake in the pancreas of Brown Norway rats compared to [Lys40(DTPA)]exendin-3 (182.7 \u00b1 42.3 kBq vs 28.8 \u00b1 6.0 kBq, p &amp;lt; 0.001). Visualization of the pancreas on SPECT was improved using hexendin(40\u201345), due to the higher count rate, achieved at the same peptide dose. In conclusion, hexendin(40\u201345) showed an improved visualization of the pancreas with SPECT. This tracer holds promise to sensitively and specifically detect small variations in BCM.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.7b00853","type":"journal-article","created":{"date-parts":[[2017,12,11]],"date-time":"2017-12-11T07:08:27Z","timestamp":1512976107000},"page":"486-494","source":"Crossref","is-referenced-by-count":9,"title":["Enhanced Specific Activity by Multichelation of Exendin-3\nLeads To Improved Image Quality and\n                    <i>In Vivo<\/i>\n                    Beta\nCell Imaging"],"prefix":"10.1021","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4427-8664","authenticated-orcid":true,"given":"Lieke","family":"Joosten","sequence":"first","affiliation":[{"name":"Radboud University Medical Center , , PO Box 9101, ,","place":["Nijmegen, The Netherlands, 6500 HB"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten","family":"Brom","sequence":"additional","affiliation":[{"name":"Radboud University Medical Center , , PO Box 9101, ,","place":["Nijmegen, The Netherlands, 6500 HB"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke","family":"Peeters","sequence":"additional","affiliation":[{"name":"Radboud University Medical Center , , PO Box 9101, ,","place":["Nijmegen, The Netherlands, 6500 HB"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7250-0846","authenticated-orcid":true,"given":"Sandra","family":"Heskamp","sequence":"additional","affiliation":[{"name":"Radboud University Medical Center , , PO Box 9101, ,","place":["Nijmegen, The Netherlands, 6500 HB"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1110-2665","authenticated-orcid":true,"given":"Martin","family":"Be\u0301he\u0301","sequence":"additional","affiliation":[{"name":"Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institut , ,","place":["Villigen, Switzerland, 5232"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto","family":"Boerman","sequence":"additional","affiliation":[{"name":"Radboud University Medical Center , , PO Box 9101, ,","place":["Nijmegen, The Netherlands, 6500 HB"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gotthardt","sequence":"additional","affiliation":[{"name":"Radboud University Medical Center , , PO Box 9101, ,","place":["Nijmegen, The Netherlands, 6500 HB"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2017,12,11]]},"reference":[{"key":"2026090221465320600_cit1","unstructured":"http:\/\/www.who.int\/mediacentre\/factsheets\/fs312\/en\/."},{"key":"2026090221465320600_cit2","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.tem.2014.02.002","article-title":"Beta cell imaging -\na key tool in optimized diabetes prevention and treatment","volume":"25","author":"Gotthardt","year":"2014","journal-title":"Trends Endocrinol. Metab."},{"key":"2026090221465320600_cit3","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.2174\/138161210791164126","article-title":"Development\nof radiotracers for the determination of the beta-cell mass in vivo","volume":"16","author":"Brom","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"2026090221465320600_cit4","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00125-013-3155-y","article-title":"Pancreatic\nbiopsy by\nminimal tail resection in live adult patients at the onset of type\n1 diabetes: experiences from the DiViD study","volume":"57","author":"Krogvold","year":"2014","journal-title":"Diabetologia"},{"key":"2026090221465320600_cit5","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.2174\/138161210791164135","article-title":"Beta cell\nimaging\u2013why we need it and what has been achieved","volume":"16","author":"Gotthardt","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"2026090221465320600_cit6","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1007\/s00125-016-3959-7","article-title":"In vivo\nimaging of beta\ncells with radiotracers: state of the art, prospects and recommendations\nfor development and use","volume":"59","author":"Eriksson","year":"2016","journal-title":"Diabetologia"},{"key":"2026090221465320600_cit7","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s00125-012-2491-7","article-title":"Obstacles on the way\nto the clinical visualisation of beta cells: looking for the Aeneas\nof molecular imaging to navigate between Scylla and Charybdis","volume":"55","author":"Andralojc","year":"2012","journal-title":"Diabetologia"},{"key":"2026090221465320600_cit8","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.2174\/138161210791164081","article-title":"What are the\npotential benefits of clinical beta-cell imaging in diabetes mellitus?","volume":"16","author":"Goke","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"2026090221465320600_cit9","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1007\/s00259-016-3592-1","article-title":"Targets and probes\nfor non-invasive\nimaging of beta-cells","volume":"44","author":"Jodal","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol.\nImaging"},{"key":"2026090221465320600_cit10","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ejrad.2009.01.044","article-title":"Advances in\nbeta-cell imaging","volume":"70","author":"Moore","year":"2009","journal-title":"Eur. J. Radiol."},{"key":"2026090221465320600_cit11","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1007\/s00125-014-3166-3","article-title":"Non-invasive quantification\nof the beta cell mass by SPECT with 111In-labelled exendin","volume":"57","author":"Brom","year":"2014","journal-title":"Diabetologia"},{"key":"2026090221465320600_cit12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000201119","article-title":"Detection of the human\nglucagon-like peptide 1(7\u201336) amide\nreceptor on insulinoma-derived cell membranes","volume":"55","author":"Lankat-Buttgereit","year":"2004","journal-title":"Digestion"},{"key":"2026090221465320600_cit13","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00259-003-1184-3","article-title":"Concomitant expression\nof several peptide receptors in neuroendocrine\ntumours: molecular basis for in vivo multireceptor tumour targeting","volume":"30","author":"Reubi","year":"2003","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2026090221465320600_cit14","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s00259-009-1363-y","article-title":"68Ga-labelled exendin-3, a new agent\nfor the detection\nof insulinomas with PET","volume":"37","author":"Brom","year":"2010","journal-title":"Eur. J. Nucl. Med.\nMol. Imaging"},{"key":"2026090221465320600_cit15","first-page":"2025","article-title":"[Lys40(Ahx-DTPA-111In)NH2]exendin-4,\na very promising ligand for glucagon-like peptide-1 (GLP-1) receptor\ntargeting","volume":"47","author":"Wild","year":"2006","journal-title":"J Nucl Med."},{"key":"2026090221465320600_cit16","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1124\/jpet.103.051987","article-title":"Glucagon-like\npeptide 1 receptor agonist ZP10A increases insulin mRNA expression\nand prevents diabetic progression in db\/db mice","volume":"307","author":"Thorkildsen","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2026090221465320600_cit17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2191-219X-2-4","article-title":"Improved labelling of DTPA- and DOTA-conjugated peptides\nand antibodies with 111In in HEPES and MES buffer","volume":"2","author":"Brom","year":"2012","journal-title":"EJNMMI Res."},{"key":"2026090221465320600_cit18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13550-016-0221-8","article-title":"The effect of purification of Ga-68-labeled\nexendin\non in vivo distribution","volume":"6","author":"Brom","year":"2016","journal-title":"EJNMMI Res."},{"key":"2026090221465320600_cit19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1210\/endo.130.1.1370150","article-title":"Establishment of 2-mercaptoethanol-dependent\ndifferentiated\ninsulin-secreting cell lines","volume":"130","author":"Asfari","year":"1992","journal-title":"Endocrinology"},{"key":"2026090221465320600_cit20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/MNM.0000000000000020","article-title":"The\ninfluence of SPECT reconstruction algorithms on image quality and\ndiagnostic accuracy in phantom measurements and 99mTc-sestamibi parathyroid\nscintigraphy","volume":"35","author":"van Hoorn","year":"2014","journal-title":"Nucl. Med. Commun."},{"key":"2026090221465320600_cit21","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00259-003-1142-0","article-title":"Optimising\nconditions for radiolabelling of DOTA-peptides with 90Y, 111In and\n177Lu at high specific activities","volume":"30","author":"Breeman","year":"2003","journal-title":"Eur. J. Nucl.\nMed. Mol. Imaging"},{"key":"2026090221465320600_cit22","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1158\/0008-5472.CAN-14-3477","article-title":"Noninvasive\nImaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies","volume":"75","author":"Heskamp","year":"2015","journal-title":"Cancer Res."},{"key":"2026090221465320600_cit23","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.2967\/jnumed.110.075648","article-title":"ImmunoSPECT\nand immunoPET of IGF-1R expression with the radiolabeled antibody\nR1507 in a triple-negative breast cancer model","volume":"51","author":"Heskamp","year":"2010","journal-title":"J. Nucl. Med."},{"key":"2026090221465320600_cit24","first-page":"683","article-title":"Labeling\nof monoclonal\nantibodies with samarium-153 for combined radioimmunoscintigraphy\nand radioimmunotherapy","volume":"30","author":"Boniface","year":"1989","journal-title":"J Nucl Med"}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.7b00853","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/15\/2\/486\/67090958\/acs.molpharmaceut.7b00853.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/15\/2\/486\/67090958\/acs.molpharmaceut.7b00853.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:49:40Z","timestamp":1788400180000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/15\/2\/486\/679347\/Enhanced-Specific-Activity-by-Multichelation-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,11]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,12,11]]},"published-print":{"date-parts":[[2018,2,5]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00853","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,11]]}}}